, /PRNewswire/ -- , a microbiome science company, today launched VS-01TM Vaginal Synbiotic, the first vaginal synbiotic clinically validated to rapidly establish an optimal vaginal microbiome dominated by the vagina's most protective bacteria. Dr. pioneering research has elucidated the crucial role of the vaginal microbiome in gynecological, urogenital, and reproductive health, though everyday factors like stress, sex, menstruation, and diet can disrupt its equilibrium and deplete the abundance of .
Dr. Ravel's extensive clinical data set indicates that 90% of women lack a stable microbiome dominated by , a key driver of vaginal health. Developed from Dr.
Ravel's discovery that not all strains of are equally protective, VS-01TM is formulated with an ecology of three proprietary strains of , which were identified from over 600 candidate probiotic strains for their superior efficacy in maintaining regulated pH and promoting stability in vaginal health. The launch builds on Seed's award-winning portfolio of microbiome-directed innovations and expands the company's pipeline beyond the gut. "This launch represents the very essence of why we founded Seed: to translate pioneering microbiome discoveries into life-changing health innovations," stated , Seed Health co-founder and co-CEO.
"As a woman and a mother, it is especially meaningful to accelerate advancements in an area that has been so deprioritized and systemically overlooked. The vaginal microbiome is the next frontier in wo.
